M. Ruperto López, G. Barril Cuadrado
554
24. Kalantar-‐Zadeh, K.; Block, G.; McAllister, CJ.; Humphreys, MH.; Kopple, JD.; Appetite and
inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am. J. Clin.
Nutr.
80
, 299-‐307 (2004).
25. Kalantar-‐Zadeh, K.; McAllister, CJ.; Lehn, RS.; Lee, GH.; Nissenson, AR.; Kopple, JD.; Effect of
malnutrition-‐inflammation complex syndrome on EPO hyporesponsiveness in
maintenance hemodialysis patients. Am. J Kidney Dis.
42
, 761-‐773 (2003).
26. Kalantar-‐Zadeh, K., Lee, GH.;Miller, JE.; Streja, E.; Jing, J.; Robertson, JA.; et al. Predictors of
hyporesponsiveness to erythropoiesis-‐stimulating agents in hemodialysis patients. Am. J.
Kidney Dis.
53
, 823-‐834 (2009).
27. Ho, LC.; Wang, HH.; Peng, YS.; Chiang, CK.; Huang, JW.; Hung, KY.; et al. Clinical utility of
malnutrition-‐inflammation score in maintenance hemodialysis patients: focus on
identifying the best cut-‐off point. Am. J. Nephrol.
28
, 840-‐846 (2008).
28. Alastrue, A.; Valoración de los parámetros antropométricosen nuestra población. Med. Clin.
(Barc).
78
, 407-‐415 (1982).
29. Chertow, GM.; Lazarus, JM.; Lew, NL.; Ma, L.; Lowrie, EG.; Bioimpedance norms for the
hemodialysis population. Kidney. Int.
52
,1617-‐1621 (1997).
30. Kilpatrick, RD.; Critchlow, CW.; Fishbane, S.; Besarab, A.; Stehman-‐Breen, C.; Krishnan, M.;
et al. Greater epoetin alfa responsiveness is associated with improved survival in
hemodialysis patients. Clin. J. Am. Soc. Nephrol.
3
, 1077-‐1083 (2008).
31. Jelkmann, WE.; Fandrey, J.; Frede, S.; Pagel, H.; Inhibition of erythropoietin production by
cytokines. Implications for the anemia involved in inflammatory states. Ann. NY Acad.
Sci.
15
, 300-‐309 (1994).
32. Goicoechea, M.; Martin, J.; Des, P.; Quiroga, JA.; Ortiz, A.; Carreno, V.; et al. Role of cytokines
in the response to erythropoietin in hemodialysis patients. Kidney Int.
54
, 1337-‐1343
(1998).
33. Panichi, V.; Rosati, A.; Bigazzi, R.; Paoletti, S.; Mantuano, E.; Beati, S.; et al. Anaemia and
resistance to erythropoiesis-‐stimulating agents as prognostic factors in haemodialysis
patients: results from the RISCAVID study. Nephrol. Dial. Transplant.
26
, 2641-‐2648
(2011).
34. Barany, P.; Vino-‐Filho, JC.; Bergstrom, J.; High C-‐reactive protein is a strong predictor of
resistance to erythropoietin in hemodialysis patients. Am. J. Kidney Dis.
29
, 565-‐568
(1997).
35. Gracia-‐Iguacel, C.; Gonzalez-‐Parra, E.; Perez-‐Gomez, MV.; Mahillo, I.; Egido, J.; Ortiz, A.; et al.
Prevalence of protein-‐energy wasting syndrome and its association with mortality in
haemodialysis patients in a centre in Spain. Nefrologia.
33
, 495-‐505 (2013).
36. Akgul, A.; Bilgic, A.; Sezer, S.; Ozdemir, FN.; Olcay, I.; Arat, Z.; et al. Effect of protein-‐energy
malnutrition on erythropoietin requirement in maintenance hemodialysis patients.
Hemodial. Int.
11
, 198-‐203 (2007).
37. Cuesta, GC.; Poveda-‐Andres, JL.; Garcia, PJ.; Roma, SE.;Cost minimisation analysis for
darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis.
Farm. Hosp.
34
, 68-‐75 (2010).
38. Sitter, T.; Bergner, A.; Schiffl, H. Dialysate related cytokine induction and response to
recombinant human erythropoietin in haemodialysis patients.
Nephrol.
Dial.
Transplant.
15
, 1207-‐1211 (2000).
39. Panichi, V.; Rosati, A.; Paoletti, S.; Ferrandello, P.; Migliori, M.; Beati, S.; et al. A vitamin E-‐
coated polysulfone membrane reduces serum levels of inflammatory markers and
resistance to erythropoietin-‐stimulating agents in hemodialysis patients: results of a
randomized cross-‐over multicenter trial. Blood. Purif.
32
, 7-‐14 (2011).
